相关实验视频

Updated: Jun 23, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

患有先进非小细胞肺癌,接受一线全身疗法治疗的患者的特异性反应和抵抗模式

Lauren Julia Brown^1,2,3,4, Julie Ahn^2,5, Bo Gao^1,2,3

¹Department of Medical Oncology, Westmead Hospital, Sydney, NSW 2145, Australia.

|June 19, 2024

概括

晚期非小细胞肺癌 (NSCLC) 的骨转移与免疫检查点抑制剂 (ICI) 的反应和存活率较差有关. 了解器官特异性耐药性是优化NSCLC治疗策略的关键.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
翻译研究是翻译研究.

背景情况:

晚期非小细胞肺癌 (NSCLC) 患者对免疫检查点抑制剂 (ICI) 和化疗的反应不同.
转移部位分布对NSCLC治疗结果的影响尚不清楚.

研究的目的:

为了研究转移的位置与治疗反应和治疗进展之间的关联,在患有不可切除的III/IV期NSCLC的患者中.
评估转移部位如何影响包括ICI在内的一线全身治疗的结果.

主要方法:

对285名接受一线全身治疗的无法切除的III/IV期非小细胞核癌患者进行了回顾性队列研究.
对人口统计学,瘤特征 (转移部位,大小,体积),治疗和结果的分析,包括器官部位特异性反应率,客观反应率 (ORR),无进展生存率 (PFS) 和整体生存率 (OS) 的分析.

主要成果:

患有骨转移的患者经历了ORR,PFS和OS的减少,主要抵抗率更高.
骨或肝转移与治疗ICI (有或没有化疗) 时的短寿命相关,但不仅仅是化疗.
研究结果表明,在特定转移部位的治疗耐药性的免疫基础.

结论:

转移部位,特别是骨,在接受ICI的晚期NSCLC患者中显著影响治疗疗效和生存率.
在NSCLC中器官特异性耐药机制需要进一步研究以优化免疫疗法组合和治疗顺序.

关键词:

在NSCLCLC中,我们可以看到NSCLCLC.骨转移发生在骨髓中.大脑转移是大脑转移.化学免疫疗法化学免疫疗法免疫疗法免疫疗法肝脏转移的发生.辐射疗法辐射疗法

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...